Loss of Cdx2 expression in primary tumors and lymph node metastases is specific for mismatch repair-deficiency in colorectal cancer

Frontiers in Oncology

Volumn 3 OCT, Issue , 2013, Pages

  Dawson, Heather ^a   Koelzer, Viktor H ^a   Lukesch, Anne C ^b   Mallaev, Makhmudbek ^b   Inderbitzin, Daniel ^b,c   Lugli, Alessandro ^a   Zlobec, Inti ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Spital Bern Tiefenau   (Switzerland)

Author keywords

Cdx2; Colorectal cancer; Microsatellite instability; Mismatch repair

Indexed keywords

TRANSCRIPTION FACTOR CDX2;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISMATCH REPAIR; OVERALL SURVIVAL; PERINEURAL INVASION; PREDICTIVE VALUE; PRIMARY TUMOR; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY; YOUNG ADULT;

EID: 84891072642     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00265     Document Type: Article

References (28)

1. Jass JR. Molecular heterogeneity of colorectal cancer: implications for cancer control. Surg Oncol (2007) 16(Suppl 1):S7-9. doi:10.1016/j.suronc.2007.10.039
2. Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol (2013) 229:441-8. doi:10.1002/path.4139
3. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology (2007) 50:113-30. doi:10.1111/j.1365-2559.2006.02549.x
4. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology (2010) 138:2088-100. doi:10.1053/j.gastro.2009.12.066
5. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst (2001) 93:1307-13. doi:10.1093/jnci/93.17.1307
6. Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ, et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med (2010) 2:458-71. doi:10.1002/emmm.201000099
7. Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol (2011) 24:1015-22. doi:10.1038/modpathol.2011.43
8. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 96:8681-6. doi:10.1073/pnas.96.15.8681
9. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology (2002) 122:1376-87. doi:10.1053/gast.2002.32997
10. Jass JR, Young J, Leggett BA. Hyperplastic polyps and DNA microsatellite unstable cancers of the colorectum. Histopathology (2000) 37:295-301. doi:10.1046/j.1365-2559.2000.01028.x
11. Halvarsson B, Lindblom A, Rambech E, Lagerstedt K, Nilbert M. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Fam Cancer (2006) 5:353-8. doi:10.1007/s10689-006-0005-9
12. Pedroni M, Sala E, Scarselli A, Borghi F, Menigatti M, Benatti P, et al. Microsatellite instability and mismatch-repair protein expression in hereditary and sporadic colorectal carcinogenesis. Cancer Res (2001) 61:896-9.
13. De Lott LB, Morrison C, Suster S, Cohn DE, Frankel WL. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med (2005) 129:1100-5.
14. Lugli A, Tzankov A, Zlobec I, Terracciano LM. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol (2008) 21:1403-12. doi:10.1038/modpathol.2008.117
15. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol (2003) 27:303-10. doi:10.1097/00000478-200303000-00003
16. Brabletz T, Spaderna S, Kolb J, Hlubek F, Faller G, Bruns CJ, et al. Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression. Cancer Res (2004) 64:6973-7. doi:10.1158/0008-5472.CAN-04-1132
17. Funakoshi S, Kong J, Crissey MA, Dang L, Dang D, Lynch JP. Intestine-specific transcription factor Cdx2 induces E-cadherin function by enhancing the trafficking of E-cadherin to the cell membrane. Am J Physiol Gastrointest Liver Physiol (2010) 299:G1054-67. doi:10.1152/ajpgi.00297.2010
18. Gross I, Duluc I, Benameur T, Calon A, Martin E, Brabletz T, et al. The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells. Oncogene (2008) 27:107-15. doi:10.1038/sj.onc.1210601
19. Guo RJ, Funakoshi S, Lee HH, Kong J, Lynch JP. The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex. Carcinogenesis (2010) 31:159-66. doi:10.1093/carcin/bgp213
20. Hinkel I, Duluc I, Martin E, Guenot D, Freund JN, Gross I. Cdx2 controls expression of the protocadherin Mucdhl, an inhibitor of growth and beta-catenin activity in colon cancer cells. Gastroenterology (2012) 142(875-85):e873. doi:10.1053/j.gastro.2011.12.037
21. Zheng JB, Sun XJ, Qi J, Li SS, Wang W, Ren HL, et al. Effects of homeodomain protein CDX2 expression on the proliferation and migration of lovo colon cancer cells. Pathol Oncol Res (2011) 17:743-51. doi:10.1007/s12253-011-9380-0
22. Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res (2009) 15:4665-73. doi:10.1158/1078-0432.CCR-09-0401
23. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer (2010) 127:367-80. doi:10.1002/ijc.25042
24. Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol (2013). doi:10.1038/modpathol.2013.101
25. Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high,-low, and-negative colorectal cancers based on protein marker expression and molecular features. J Pathol (2011) 225:336-43. doi:10.1002/path.2879
26. Choi BJ, Kim CJ, Cho YG, Song JH, Kim SY, Nam SW, et al. Altered expression of CDX2 in colorectal cancers. APMIS (2006) 114:50-4. doi:10.1111/j.1600-0463.2006.apm_292.x
27. Hong KD, Lee D, Lee Y, Lee SI, Moon HY. Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. Am Surg (2013) 79:353-60.
28. Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol (2010) 37:707-18. doi:10.3892/ijo_00000720